Fractional Anisotropy is a More Sensitive Diagnostic Biomarker Than Mean Kurtosis for Patients with Parkinson Disease with Cognitive Dysfunction: A Diffusional Kurtosis Map Tract-Based Spatial Statistics Study

References

1. 1.↵
   1. Crockett R,
   2. Wilkins K,
   3. Aditham S, et al

   . No laughing white matter: cortical cholinergic pathways and cognitive decline in Parkinson’s disease. medRxiv May 2, 2023 [Epub ahead of Print] doi:10.1101/2023.05.01.23289348 pmid:37205443

   Abstract/FREE Full Text
2. 2.↵
   1. Wallace E,
   2. Segerstrom S,
   3. van HC, et al

   . Meta-analysis of cognition in Parkinson's disease mild cognitive impairment and dementia progression. Neuropsychol Rev 2022;32:149–60 doi:10.1007/s11065-021-09502-7 pmid:33860906

   CrossRefPubMed
3. 3.↵
   1. Postuma R,
   2. Berg D,
   3. Stern M, et al

   . MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord 2015;30:1591–601 doi:10.1002/mds.26424 pmid:26474316

   CrossRefPubMed
4. 4.↵
   1. Goldman J,
   2. Holden S,
   3. Litvan I, et al

   . Evolution of diagnostic criteria and assessments for Parkinson’s disease mild cognitive impairment. Mov Disord 2018;33:503–10 doi:10.1002/mds.27323 pmid:29488270

   CrossRefPubMed
5. 5.↵
   1. Szeto J,
   2. Walton C,
   3. Rizos A, et al

   . Dementia in long-term Parkinson’s disease patients: a multicentre retrospective study. NPJ Parkinsons Dis 2020;6:2 doi:10.1038/s41531-019-0106-4 pmid:31934610

   CrossRefPubMed
6. 6.↵
   1. Saredakis D,
   2. Collins-Praino L,
   3. Gutteridge D, et al

   . Conversion to MCI and dementia in Parkinson’s disease: a systematic review and meta-analysis. Parkinsonism Relat Disord 2019;65:20–31 doi:10.1016/j.parkreldis.2019.04.020 pmid:31109727

   CrossRefPubMed
7. 7.↵
   1. Aarsland D,
   2. Batzu L,
   3. Halliday G, et al

   . Parkinson disease-associated cognitive impairment. Nat Rev Dis Primers 2021;7:47 doi:10.1038/s41572-021-00280-3 pmid:34210995

   CrossRefPubMed
8. 8.↵
   1. Zhang Y,
   2. Burock MA

   . Diffusion tensor imaging in Parkinson’s disease and Parkinsonian syndrome: a systematic review. Front Neurol 2020;11:531993 doi:10.3389/fneur.2020.531993 pmid:33101169

   CrossRefPubMed
9. 9.↵
   1. Arab A,
   2. Ruda-Kucerova J,
   3. Minsterova A, et al

   . Diffusion kurtosis imaging detects microstructural changes in a methamphetamine-induced mouse model of Parkinson's disease. Neurotox Res 2019;36:724–35 doi:10.1007/s12640-019-00068-0 pmid:31209787

   CrossRefPubMed
10. 10.↵
    1. Taha H,
    2. Chad J,
    3. Chen J

    . DKI enhances the sensitivity and interpretability of age-related DTI patterns in the white matter of UK biobank participants. Neurobiol Aging 2022;115:39–49 doi:10.1016/j.neurobiolaging.2022.03.008 pmid:35468551

    CrossRefPubMed
11. 11.↵
    1. Jelescu I,
    2. Budde M

    . Design and validation of diffusion MRI models of white matter. Front Phys 2017;28:61 doi:10.3389/fphy.2017.00061 pmid:29755979

    CrossRefPubMed
12. 12.↵
    1. Huang S,
    2. Dong Y,
    3. Zhao J

    . The mean kurtosis (MK) is more sensitive diagnostic biomarker than fractional anisotropy (FA) for Parkinson's disease: a diagnostic performance study and meta-analysis. Medicine (Baltimore) 2022;101:e31312 doi:10.1097/MD.0000000000031312 pmid:36397320

    CrossRefPubMed
13. 13.↵
    1. Litvan I,
    2. Goldman J,
    3. Tröster A, et al

    . Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement Disorder Society Task Force Guidelines. Mov Disord 2012;27:349–56 doi:10.1002/mds.24893 pmid:22275317

    CrossRefPubMed
14. 14.↵
    1. Emre M,
    2. Aarsland D,
    3. Brown R, et al

    . Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 2007;22:1689–707;quiz 1837 doi:10.1002/mds.21507 pmid:17542011

    CrossRefPubMedWeb of Science
15. 15.↵
    1. Arevalo-Rodriguez I,
    2. Smailagic N,
    3. Roqué-Figuls M, et al

    . Mini-Mental State Examination (MMSE) for the early detection of dementia in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev 2021;7:Cd010783 doi:10.1002/14651858.CD010783.pub3 pmid:34313331

    CrossRefPubMed
16. 16.↵
    1. Woolrich M,
    2. Jbabdi S,
    3. Patenaude B, et al

    . Bayesian analysis of neuroimaging data in FSL. Neuroimage 2009;45:S173–86 doi:10.1016/j.neuroimage.2008.10.055 pmid:19059349

    CrossRefPubMedWeb of Science
17. 17.↵
    1. Smith S,
    2. Jenkinson M,
    3. Woolrich M, et al

    . Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 2004;23(Suppl 1):S208–19 doi:10.1016/j.neuroimage.2004.07.051 pmid:15501092

    CrossRefPubMedWeb of Science
18. 18.↵
    1. Melzer T,
    2. Watts R,
    3. MacAskill M, et al

    . White matter microstructure deteriorates across cognitive stages in Parkinson disease. Neurology 2013;80:1841–49 doi:10.1212/WNL.0b013e3182929f62 pmid:23596076

    Abstract/FREE Full Text
19. 19.↵
    1. Lee J,
    2. Park H,
    3. Park B, et al

    . A comparative analysis of cognitive profiles and white-matter alterations using voxel-based diffusion tensor imaging between patients with Parkinson’s disease dementia and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2010;81:320–26 doi:10.1136/jnnp.2009.184747 pmid:19828477

    Abstract/FREE Full Text
20. 20.↵
    1. Minett T,
    2. Su L,
    3. Mak E, et al

    . Longitudinal diffusion tensor imaging changes in early Parkinson’s disease: ICICLE-PD study. J Neurol 2018;265:1528–39 doi:10.1007/s00415-018-8873-0 pmid:29696499

    CrossRefPubMed
21. 21.↵
    1. Li Q,
    2. Wu K,
    3. Xu J, et al

    . White matter damage in patients with mild cognitive impairment in Parkinson’s disease. Quant Imaging Med Surg 2022;12:1290–98 doi:10.21037/qims-21-579 pmid:35111624

    CrossRefPubMed
22. 22.↵
    1. Chen B,
    2. Fan G,
    3. Liu H, et al

    . Changes in anatomical and functional connectivity of Parkinson’s disease patients according to cognitive status. Eur J Radiol 2015;84:1318–24 doi:10.1016/j.ejrad.2015.04.014 pmid:25963506

    CrossRefPubMed
23. 23.↵
    1. Helpern J,
    2. Adisetiyo V,
    3. Falangola M, et al

    . Preliminary evidence of altered gray and white matter microstructural development in the frontal lobe of adolescents with attention-deficit hyperactivity disorder: a diffusional kurtosis imaging study. J Magn Reson Imaging 2011;33:17–23 doi:10.1002/jmri.22397 pmid:21182116

    CrossRefPubMed
24. 24.↵
    1. Kamagata K,
    2. Zalesky A,
    3. Hatano T, et al

    . Gray matter abnormalities in idiopathic Parkinson’s disease: evaluation by diffusional kurtosis imaging and neurite orientation dispersion and density imaging. Hum Brain Mapp 2017;38:3704–22 doi:10.1002/hbm.23628 pmid:28470878

    CrossRefPubMed
25. 25.↵
    1. Zhang G,
    2. Zhang Y,
    3. Zhang C, et al

    . Diffusion kurtosis imaging of substantia nigra is a sensitive method for early diagnosis and disease evaluation in Parkinson’s sisease. Parkinsons Dis 2015;2015:207624 pmid:26770867

    CrossRefPubMed
26. 26.↵
    1. Caligiore D,
    2. Helmich R,
    3. Hallett M, et al

    . Parkinson's disease as a system-level disorder. NPJ Parkinsons Dis 2016;2:16025 doi:10.1038/npjparkd.2016.25 pmid:28725705

    CrossRefPubMed
27. 27.↵
    1. Choong C,
    2. Mochizuki H

    . Neuropathology of α-synuclein in Parkinson’s disease. Neuropathology 2022;42:93–103 doi:10.1111/neup.12812 pmid:35362115

    CrossRefPubMed
28. 28.↵
    1. Bidesi N,
    2. Vang AI,
    3. Windhorst A, et al

    . The role of neuroimaging in Parkinson’s disease. J Neurochem 2021;159:660–89 doi:10.1111/jnc.15516 pmid:34532856

    CrossRefPubMed
29. 29.↵
    1. Pozorski V,
    2. Oh J,
    3. Adluru N, et al

    . Longitudinal white matter microstructural change in Parkinson’s disease. Hum Brain Mapp 2018;39:4150–61 doi:10.1002/hbm.24239 pmid:29952102

    CrossRefPubMed
30. 30.↵
    1. Pan L,
    2. Li C,
    3. Meng L, et al

    . Tau accelerates α-synuclein aggregation and spreading in Parkinson’s disease. Brain 2022;145:3454–71 doi:10.1093/brain/awac171 pmid:35552614

    CrossRefPubMed
31. 31.↵
    1. Taylor K,
    2. Sambataro F,
    3. Boess F, et al

    . Progressive decline in gray and white matter integrity in de novo Parkinson’s disease: an analysis of longitudinal Parkinson Progression Markers Initiative diffusion tensor imaging data. Front Aging Neurosci 2018;10:318 doi:10.3389/fnagi.2018.00318 pmid:30349475

    CrossRefPubMed
32. 32.↵
    1. Zheng Z,
    2. Shemmassian S,
    3. Wijekoon C, et al

    . DTI correlates of distinct cognitive impairments in Parkinson’s disease. Hum Brain Mapp 2014;35:1325–33 doi:10.1002/hbm.22256 pmid:23417856

    CrossRefPubMed